Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 10,000 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $69.07, for a total transaction of $690,700.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $53,030,564.60. This trade represents a 1.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Monday, June 1st, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $67.58, for a total transaction of $1,351,600.00.
• On Wednesday, May 13th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.19, for a total transaction of $691,900.00.
• On Tuesday, May 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $71.75, for a total transaction of $1,435,000.00.
• On Monday, April 6th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $63.50, for a total transaction of $635,000.00.
• On Thursday, April 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $64.24, for a total transaction of $1,284,800.00.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $69.82 on Thursday. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The company has a market capitalization of $8.28 billion, a P/E ratio of 25.12, a P/E/G ratio of 0.27 and a beta of 0.88. Halozyme Therapeutics, Inc. has a 12-month low of $51.06 and a 12-month high of $82.22. The firm has a 50-day moving average price of $66.44 and a two-hundred day moving average price of $68.71.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The firm had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business’s revenue for the quarter was up 42.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Analysts anticipate that Halozyme Therapeutics, Inc. will post 7.6 earnings per share for the current year.

Institutional Trading of Halozyme Therapeutics

A number of hedge funds have recently added to or reduced their stakes in HALO. Measured Wealth Private Client Group LLC boosted its position in Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares in the last quarter. Larson Financial Group LLC boosted its position in Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares in the last quarter. Clearstead Advisors LLC boosted its position in Halozyme Therapeutics by 107.7% in the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 265 shares in the last quarter. Harbour Investments Inc. boosted its position in Halozyme Therapeutics by 152.5% in the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 372 shares in the last quarter. Finally, Penserra Capital Management LLC acquired a new stake in Halozyme Therapeutics in the third quarter valued at approximately $52,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics News Roundup

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised earnings estimates across multiple future periods, including FY2026, FY2027, and FY2028, suggesting improving profit expectations for Halozyme Therapeutics. Halozyme Therapeutics article
• Positive Sentiment: Analysts now see stronger earnings in several quarters, including Q1 2027, Q2 2027, Q3 2027, and Q4 2027, which may reinforce the stock’s valuation outlook. Halozyme Therapeutics article
• Neutral Sentiment: There was also a small increase in one near-term estimate for Q4 2026, while Q2 2026 was trimmed slightly and Q1 2028 was revised lower, indicating a mostly constructive but not uniformly higher forecast profile. Halozyme Therapeutics article
• Neutral Sentiment: Recent insider sales by the CEO and a director were disclosed, but both were executed under pre-arranged 10b5-1 plans, which usually makes them less concerning to investors than discretionary selling. Halozyme Therapeutics article

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Wells Fargo & Company boosted their price objective on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a report on Thursday, February 19th. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Finally, Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday. Eight equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.